<DOC>
	<DOCNO>NCT02377271</DOCNO>
	<brief_summary>Acute ischemic optic neuropathy second lead cause optic neuropathy glaucoma population age 50 year . The visual prognosis condition unfavorable great majority case , significant effect visual field vision . The severity unilateral condition also associate bilateralization 15 % 5 year . There effective treatment acute phase disease reduce rate bilateralization . In context , essential develop new therapeutic strategy acute phase disease reduce anatomical optic nerve damage .</brief_summary>
	<brief_title>ENDOTHELION Study Group : Effect Bosentan NAION Patients</brief_title>
	<detailed_description>The main objective study compare treatment bosentan placebo 8 week recovery anatomical criterion ( RFNL OCT , optic atrophy ) functional ( visual acuity , visual field ) . The primary endpoint improvement visual field , major criterion affect visual function disease . The evaluation bosentan mainly 8 week treatment order ass effectiveness drug treatment absence continuous positive airway pressure ( set three month necessary , feasible confound factor evaluation result ) , period three month sufficient assess anatomical functional recovery ( disappearance papilledema ) .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>non arteritic ischemic optic neuropathy ( NAION ) onset &lt; 21 day pregnant woman intercurrent ocular pathology</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Bosentan</keyword>
</DOC>